PHVS Stock Risk & Deep Value Analysis
Pharvaris NV
DVR Score
out of 10
What You Need to Know About PHVS Stock
We analyzed Pharvaris NV using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PHVS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PHVS Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is further regulatory delays or an unfavorable outcome from the FDA post-resubmission. This would push out revenue generation significantly, exacerbating cash burn and necessitating highly dilutive capital raises, potentially crippling the company's valuation and long-term prospects.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
FDA Complete Response Letter (CRL) in April 2024, indicating regulatory hurdles and delays.
- ⚠
Continued high cash burn without revenue generation, leading to potential future dilution.
- ⚠
Dependence on a single lead product (sebetralstat) for near-term success.
Upcoming Risk Events
- 📅
Further delays in FDA approval or another CRL
- 📅
Slower-than-expected commercial uptake post-launch
- 📅
Competitive product launches or advancements
- 📅
Q1 2026 Earnings: Cash burn exceeding expectations
When to Reconsider
- 🚪
Exit if another significant regulatory setback occurs (e.g., a second CRL or outright rejection).
- 🚪
Sell if cash runway falls below 4 quarters without a clear, non-dilutive financing plan.
- 🚪
Exit if commercial launch is significantly delayed beyond 2027 or initial sales data disappoints.
Unlock PHVS Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Pharvaris (PHVS) represents a high-risk, high-reward investment banking on the eventual FDA approval and successful commercialization of sebetralstat. Despite regulatory delays (CRL in April 2024), the oral, on-demand profile of sebetralstat still addresses a critical unmet need in HAE, positioning it for potential market leadership. The investment thesis hinges on the company's ability to navigate the resubmission process efficiently and execute a strong commercial launch, with significant upside if these milestones are met.
Is PHVS Stock Undervalued?
Unlock the full AI analysis for PHVS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PHVS Price Targets & Strategy
12-Month Target
$35.00
Bull Case
$55.00
Bear Case
$15.00
Valuation Basis
Based on 2.5x estimated 2029 peak sales of $1.5B, discounted to 2027 launch, then applying a forward P/S multiple for a pre-commercial biotech post-CRL.
Entry Strategy
Dollar-cost average between $20-$25 (testing recent support levels). Await clear positive regulatory updates before significant allocation.
Exit Strategy
Take 50% profit at $45, re-evaluate after FDA approval and initial sales data. Stop loss at $18 if further regulatory setbacks occur or cash runway significantly shortens.
Portfolio Allocation
3-5% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does PHVS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable (but at risk of erosion due to regulatory delays allowing competitors to advance)
Moat Sources
2 Identified
The moat, primarily derived from patent protection and the first-mover advantage of an oral, on-demand therapy, is durable once approved. However, the regulatory delays for sebetralstat have created an opening for competitors, potentially eroding its first-mover status.
Moat Erosion Risks
- •Competitors launching similar oral HAE therapies during Pharvaris's regulatory delay.
- •Patent challenges or expiration impacting sebetralstat's exclusivity.
- •Slower-than-expected physician adoption post-launch.
PHVS Competitive Moat Analysis
Sign up to see competitive advantages
PHVS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Retail sentiment likely turned bearish post-CRL, with cautious optimism returning on resubmission news.
Institutional Sentiment
Neutral. Analyst downgrades and price target reductions occurred post-CRL; some recovery expected on resubmission, but cautious.
Insider Activity (Form 4)
No recent significant insider buying or selling activity reported that indicates a strong directional conviction following the CRL. Activity remains sporadic.
Options Flow
Normal options activity with a slight increase in call volume indicating some speculative bullishness around regulatory clarity, but put/call ratio remains balanced.
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026)
Surprise Probability
Low (as focus is on regulatory and cash, not revenue beats)
Historical Earnings Pattern
Stock price has been highly reactive to regulatory news (PDUFA, CRL) rather than earnings reports. Earnings typically show consistent losses, with movement driven by forward guidance or pipeline updates.
Key Metrics to Watch
Competitive Position
Top Competitor
BioCryst Pharmaceuticals (BCRX)
Market Share Trend
Not yet commercial, so no market share. Potential to gain significant share if approved due to oral, on-demand profile.
Valuation vs Peers
Currently trading at a discount on a future P/S basis compared to peers with approved oral HAE treatments, reflecting its delayed regulatory status and higher risk.
Competitive Advantages
- •Oral, on-demand administration for HAE (convenience over injectables)
- •Novel mechanism of action (plasma kallikrein inhibition)
- •Positive efficacy and safety data from clinical trials for lead asset
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PHVS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early-May 2026): Focus on cash runway and resubmission update
- •Resubmission of NDA to FDA (Expected H1 2026)
- •FDA PDUFA Date for Sebetralstat (Estimated Q4 2026 / Q1 2027) post-resubmission
Medium-Term (6-18 months)
- •Sebetralstat Commercial Launch in US (post-FDA approval, estimated Q2 2027)
- •EMA Approval for Sebetralstat (Expected 2027)
- •Initial Sales Data Post-Launch
Long-Term (18+ months)
- •Global Market Expansion for Sebetralstat
- •Pipeline Expansion into New Indications/Compounds
- •Potential for Sebetralstat to become standard of care for HAE
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PHVS?
- ✓
Successful and timely FDA resubmission with a clear new PDUFA date.
- ✓
Positive initial commercial uptake data post-launch.
- ✓
Strong cash management and non-dilutive financing solutions.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Pharvaris NV (PHVS)?
As of March 31, 2026, Pharvaris NV has a DVR Score of 6.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for PHVS stock?
Our analysis rates Pharvaris NV's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the PHVS DVR analysis updated?
Our AI-powered analysis of Pharvaris NV is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 31, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PHVS (Pharvaris NV) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.